XML 23 R5.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
Consolidated Statement of Income - USD ($)
shares in Millions, $ in Millions
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues      
Revenues $ 42,857 $ 44,915 $ 39,211 Close
Costs and operating expenses:      
Selling, general and administrative expenses 8,445 8,993 8,007
Research and development expenses 1,337 1,471 1,406
Restructuring and other costs 459 114 197
Total costs and operating expenses 35,998 36,522 29,183 Close
Operating income 6,859 8,393 10,028 Close
Interest income 879 272 43 Close
Interest expense (1,375) (726) (536) Close
Other income/(expense) (65) (104) (694) CloseClose
Total Other Income Expenses -561.0 -558.0 -1187.0 0.0 0 Close
Income before income taxes 6,298 7,835 8,841 CloseClose
Provision for income taxes (284) (703) (1,109) Close
Equity in earnings/(losses) of unconsolidated entities (59) (172) (4) Close
Net income 5,955 6,960 7,728 Close
Less: net (losses) income attributable to noncontrolling interests and redeemable noncontrolling interest (40) 10 3
Net income attributable to Thermo Fisher Scientific Inc. $ 5,995 $ 6,950 $ 7,725
Earnings per share attributable to Thermo Fisher Scientific Inc.      
Basic (in dollars per share) $ 15.52 $ 17.75 $ 19.62
Diluted (in dollars per share) $ 15.45 $ 17.63 $ 19.46
Weighted average shares      
Basic (in shares) 386 392 394
Diluted (in shares) 388 394 397
Product revenues      
Revenues      
Revenues $ 25,243 $ 28,548 $ 30,361
Costs and operating expenses:      
Cost of revenues 13,168 14,247 13,594
Service revenues      
Revenues      
Revenues 17,614 16,367 8,850
Costs and operating expenses:      
Cost of revenues $ 12,589 $ 11,697 $ 5,979